Extended Data Fig. 7: Pathway alterations in the proteomic subtypes. | Nature

Extended Data Fig. 7: Pathway alterations in the proteomic subtypes.

From: Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma

Extended Data Fig. 7

a, Heat map of alteration pathways in the proteomic subtypes. Left, alteration pathways identified from the proteome. Right, alteration pathways identified from the phospho-proteome. Colour of each cell represents the average ssGSEA enrichment scores of that subtype; red denotes activation and blue denotes inhibition. Blank cells represent non-enrichment. b, Details of alteration scores of integrin proteins, extracellular matrix proteins, metalloproteinase proteins and glycolysis proteins shown in Fig. 3a. c, Network diagram depicting the interaction of the Rho GTPase signalling pathway. The pink node represents proteins expressed at higher levels in the S-III tumours than in the S-I and S-II tumours; a red node border indicates the hyper-phosphorylation of that protein. d, Identification and quantification of hyper-phosphorylation sites for Rho GTPase activators (FGD3, DOCK2 and ARHGEF2) in S-I (n = 35), S-II (n = 30) and S-III (n = 29) tumours. In the box plots, the middle bar represents the median, and the box represents the interquartile range; bars extend to 1.5× the interquartile range. A grey circle under the box plot indicates that this phosphorylation site is not identified in these samples. P values are calculated by two-sided Wilcoxon rank-sum test.

Source data